HUMANIZED ANTIBODY AGAINST TNFR2 AND USE THEREOF

Title:

HUMANIZED ANTIBODY AGAINST TNFR2 AND USE THEREOF

Document Type and Number:

WIPO Patent Application WO/2022/161425

Kind Code:

A1

Abstract:

Disclosed in the present invention are a humanized antibody that can specifically bind to TNFR2, or an antigen-binding fragment thereof. The humanized antibody or antigen-binding fragment thereof can regulate the function of immune cells and can be used in a drug for treating diseases related to immune abnormalities, such as tumors.

Inventors:

ZHAO XIAOFENG (CN)
LU SHIQIANG (CN)
CAO ZHUOXIAO (CN)
TANG RENHONG (CN)
REN JINSHENG (CN)

Application Number:

PCT/CN2022/074228

Publication Date:

August 04, 2022

Filing Date:

January 27, 2022

Export Citation:

Click for automatic bibliography generation Help

Assignee:

JIANGSU SIMCERE PHARM CO LTD (CN)

International Classes:

C07K16/28; A61K39/395; A61P35/00; A61P35/04; C12N15/13

Domestic Patent References:

WO2020089474A1

2020-05-07

Foreign References:

CN109476745A	2019-03-15
CN202110140980A	2021-01-29
CN202111016307A	2021-08-31
CN2020106057W	2020-07-31

Other References:

WAHL ET AL., J.NUCL.MED, vol. 24, 1983, pages 316
WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546
BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426
HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, PUBLIC HEALTH SERVICE
MORRISON, SCIENCE, vol. 229, no. 4719, 1985, pages 1202 - 7
OI ET AL., BIO TECHNIQUES, vol. 4, 1986, pages 214 - 221
GILLIES ET AL., J IMMUNOL METHODS, vol. 125, 1985, pages 191 - 202
ZARAGOZA B ET AL., NAT MED, vol. 22, no. 1, January 2016 (2016-01-01), pages 16 - 7